Peter Kind and Loren Frank discuss their work using SFARI’s genetic rat models and their views on how these models will aid autism research.
SFARI Investigator Karen Parker discusses her preclinical and clinical research on the neuropeptides arginine vasopressin and oxytocin as potential biomarkers and treatment strategies for autism spectrum disorder.
SFARI Investigator Dan Feldman discusses the E-I ratio hypothesis in autism and his lab’s recent studies that aimed to test it.
SFARI Investigator Seth Shipman discusses his lab’s research on the molecular and cellular mechanisms shaping brain development and how the Bridge to Independence Award is helping him launch his independent research career.
Paul Wang, Deputy Director of Clinical Research Associates, L.L.C. (CRA), discusses the research that CRA supports, including human and animal studies using arbaclofen, a potential drug treatment for autism.
SFARI Investigator David Ginty talks about the links between deficits in the sense of touch, tactile hypersensitivity, and alterations in social behaviors in autism.
Sharmila Banerjee-Basu, founder and chief scientific officer at MindSpec Inc., discusses SFARI Gene and how it is changing the face of autism genetics research.
SFARI Investigator Sung Han discusses his lab’s work and how the Bridge to Independence Award helped him launch his independent career in autism research.
SFARI Investigator Liqun Luo discusses the neurodevelopmental disorder Smith-Magenis syndrome and his lab’s efforts to understand its underlying biology.
Pamela Feliciano discusses the motivation behind SPARK and insights gained from the initial phases of the project.